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Abstract
Objective—To report the rare but distinct clinical and neuropathological phenotype of non-
familial, rapidly progressive parkinsonism and dementia associated with frontotemporal lobar 
degeneration with motor neuron disease (FTLD-MND).
Methods—Subjects included two 70-year-old women presenting with rapidly progressive severe 
postural instability, axial-predominant parkinsonism, oculomotor dysfunction and frontal-
predominant dementia with language impairment and pseudobulbar palsy. One had diffuse 
weakness without signs of lower motor neuron disease. Post-mortem evaluations included 
immunohistochemistry with antiphospho-TAR DNA-binding protein 43 (TDP-43) and genetic 
analysis of the TARDBP and PGRN genes.
Results—Subjects died within 14 months from symptom onset. TDP-43-positive neuronal 
intracytoplasmic inclusions were prominent in the primary motor cortex, granule cell layer of the 
hippocampus, and several cranial and spinal cord nuclei. TDP-43 globular glial inclusions (GGI) 
were identified in one case. There were no mutations in PGRN or TARDBP genes.
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Conclusions—FTLD-MND due to TDP-43-proteinopathy should be considered in patients with 
rapidly progressive parkinsonism and dementia phenotype, especially when aphasia and/or 
weakness are also present.
Rapidly progressive dementia with parkinsonism has been associated with several 
pathological substrates of neurodegeneration including frontotemporal lobar degeneration 
(FTLD) with or without motor neuron disease (MND), Alzheimer’s disease, diffuse Lewy 
body disease, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and 
Creutzfeldt–Jakob disease.1 Traditionally, Parkinsonian phenotypes with frontal-
predominant dementia have been considered highly predictive of τ-positive 
neuropathology.23
FTLD is the most common anatomic correlate of progressive frontotemporal dementia and 
parkinsonism. Tauopathies (FTLD-τ) and TAR DNA-binding protein 43 (TDP-43)-
proteinopathies (FTLD-TDP), associated with the accumulation of either 
hyperphosphorylated τ or TDP-43 protein, respectively, account for 50% of all cases of 
FTLD (4). Neuropathological subtypes have been identified within the FTLD-τ subgroup 
(Pick’s disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), 
argyrophilic grain disease (AGD), multiple system tauopathy with presenile dementia 
(MSTD), white-matter tauopathy with globular glial inclusions (WMT-GGI)), and the 
FTLD-TDP subgroup.45
We report two cases of sporadic parkinsonism and frontotemporal dementia with unusually 
rapidly progressive disease course (within 14 months) associated with weakness and 
progressive non-fluent aphasia due to FTLD-TDP with MND. One case had a peculiar 
oligodendroglial pathological phenotype with globular glial inclusions resembling those of 
WMT-GGI5 and multiple system atrophy (MSA).6
REPORT OF CASES
Patient 1
A 70-year-old woman suffered backward falls and shortly thereafter slowed and hypophonic 
voice, word-finding difficulty, difficulty reading, dysphagia and diffuse weakness. On 
examination, 9 months after symptom onset, she had dementia (Mini-Mental State 
Examination=15/30; Frontal Assessment Battery=8/18; abnormal clock drawing test), 
pseudobulbar affect, non-fluent aphasia with agrammatism and impaired repetition. 
Supranuclear vertical gaze paresis, apraxia of eyelid closing, frontal release signs, diffuse 
hyper-reflexia and limb weakness, marked postural and gait impairment were observed (see 
online video, segment 1). There was no tongue or muscle atrophy or fasciculations. An MRI 
of the brain revealed mild diffuse cortical atrophy, predominantly affecting frontal and 
temporal lobes (figure 1A–C). EMG of the lower extremities revealed widespread 
fibrillations. She died of bronchopneumonia 14 months after symptom onset.
The weight of the fixed brain was 1250 g. Mild diffuse cortical atrophy and mildly 
depigmented substantia nigra were noted. Microscopically, moderate to severe neuronal 
loss, gliosis and superficial microvacuolar changes were observed in the prefrontal, primary 
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motor and temporal cortices and, to a lesser extent, in the parietal cortex and cingulate 
gyrus. There was severe loss of Betz cells. Mild neuronal loss and gliosis were observed in 
the hippocampus. In the brainstem, mild to moderate neuronal loss, gliosis and 
neuromelaninladen macrophages were seen in the substantia nigra and locus coeruleus, and 
moderate loss of neurons in the interstitial nucleus of the medial longitudinal fasciculus 
(iMLF), motor dorsal nucleus of the vagus nerve and hypoglossal nucleus, where Bunina 
bodies were present.
Phosphorylated TDP-43 immunohistochemistry revealed neuronal cytoplasmic inclusions 
(NCI) in several regions, including the iMLF, most abundant in the granule cell layer of the 
hippocampus (figure 1D, E). Abundant pTDP-43 pathology in the form of oligodendroglial 
cytoplasmic inclusions was seen in the lower cortical layers and, more extensively, in the 
subcortical white matter (figure 1F). Oligodendroglial inclusions had a perinuclear, crescent, 
triangular or oval appearance, resembling that of Papp–Lantos inclusions of MSA or 
oligodendroglial inclusions of WMT-GGI.56 They measured about the size of the nucleus in 
longest dimension and they were ubiquitin-positive but not visualised with H&E or silver-
staining, τ- or α-synuclein immunohistochemistry. τ-Pathology was limited to a few 
granular deposits in neurons of the subiculum. Immunohistochemistry for α-synuclein and 
β-amyloid protein was negative.
Patient 2
A 70-year-old, right-handed woman developed apathy, bradykinesia, falls, non-fluent 
aphasia, severe hypophonia and dysphagia. She had a history of dementia in two maternal 
uncles. On first examination, 9 months after symptom onset, she had dysexecutive cognitive 
impairment (Mini-Mental Status Examination=26/30; Frontal Assessment Battery=8/18), 
speech in staccato, slow and moderate dysprosody, glabellar reflex and saccadic pursuit, left 
hand ideomotor apraxia to intransitive gestures, severe axial (more than limb) rigidity, 
bradykinesia, generalised hyper-reflexia with clonus, bilateral Babinski and Hoffman signs, 
and slow, short-stepped gait associated with marked postural instability (see online video, 
segment 2). No atrophy or fasciculations were noted. Neuropsychological evaluation 
showed a Dementia Rating Scale-2 test score below the fifth percentile. Brain MRI revealed 
mild insular atrophy (figure 2A–C), and EEG displayed left temporal intermittent rhythmic 
delta activity. EMG/NCV showed no evidence of motor neuron disease. CSF examination 
was normal as 14-3-3, and cultures, including fungal and AFB, were negative. Her 
symptoms rapidly progressed. Four months later, she was mute, combative and unable to 
stand during hospitalisation. She died less than 14 months after symptom onset.
The weight of the fresh brain was 1199 g. There was mild to moderate atrophy of the frontal 
lobes and mild atrophy of the parietal and occipital lobes and parahippocampal gyrus. 
Microscopically, severe neuronal loss and mild gliosis were observed in the superior frontal, 
middle frontal and cingulate gyri and, to a lesser extent, in the superior and middle temporal 
gyri, superior parietal lobe and occipital cortex. Microvacuolar changes were observed in the 
upper frontal and temporal cortical layers and less extensively in the superior parietal lobule. 
Moderate neuronal loss was observed in the CA2 sector of the hippocampus and subiculum, 
and, more widespread, in the entorhinal and transentorhinal cortices. In the subcortical 
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nuclei, moderate to severe neuronal loss and gliosis were noted in the caudate nucleus, 
putamen, globus pallidus and amygdala, substantia nigra, locus coeruleus, reticular 
formation, motor dorsal nucleus of the vagus nerve, hypoglossal nucleus, and inferior 
olivary nucleus, as well as to a lesser extent in the thalamus and subthalamic nucleus. The 
cerebellum displayed mild loss of Purkinje cells and dentate nucleus neurons. Mild to 
moderate loss of motor neurons was seen in the spinal cord. There was extensive gliosis of 
the subcortical white matter and internal capsule.
TDP-43 immunohistochemistry revealed abundant NCI in the dentate gyrus of the 
hippocampus with ring-like perinuclear appearance in the frontal and temporal cortical layer 
II, and, to a much lesser extent, in the parietal cortex (figure 2D, E), with granular and 
occasional skein-like inclusions in a few residual upper motor neurons (figure 2F). A few 
dystrophic neurites were recognised in the caudate nucleus, and less extensively in the 
putamen and amygdala. NCIs were identified in a few remaining lower motor neurons in the 
spinal cord. τ-Immunoreactive neurofibrillar tangles were seen in the CA1 sector of the 
hippocampus, entorhinal and transentorhinal cortices, and inferior temporal cortex. No α-
synuclein or β-amyloid protein deposits were observed.
DNA analysis did not show mutations in PGRN or TARDBP genes in either case. Western 
blot analysis did not reveal the presence of abnormal, protease-resistant prion protein 
(PrP27-30).
DISCUSSION
We report two cases of an atypical PSP-like syndrome associated with FTLD-MND and 
TDP-43-proteinopathy. There is striking similarity in the clinical phenotype which is 
characterised by atypical and rapidly progressive parkinsonism and frontal dementia. Both 
subjects presented with clinical features of PSP and MND, had a rapidly progressive clinical 
course and died within 14 months from clinical onset. Although our patients had an older 
age at onset (70 years) than the median of the five cases with FTLD-MND reported within 
the rapidly progressive dementia series from the Mayo Clinic (50 years), it is important to 
note that four of these five FTLD-MND cases presented with personality and behavioural 
abnormalities in their mid-40s.1 Our patients’ presentations were clinically closer to that of 
the 67-year-old FTLD-MND woman with gait disturbances.1 Collectively, these seven cases 
would suggest that a non-behavioural, axial-predominant phenotype of FTLD-MND may be 
the more common in older subjects. Finally, although the tremorless, hypokinetic-rigid 
syndrome with early falls and oculomotor impairment described here suggested PSP, 
weakness and early pyramidal signs, severe language deficits (eg, progressive non-fluent 
aphasia (PNFA)) and rapid progression excluded the clinical diagnosis of possible or 
probable PSP, as per current criteria.7 Recent work, however, suggests that PNFA can rarely 
be part of the clinical spectrum of PSP (PSP-PNFA).8
The association of clinical PSP and MND has been described occurring either in the setting 
of an underlining tauopathy, as in atypical PSP with corticospinal degeneration (aPSP-
CSD),9 or TDP-43 proteinopathy.1011 Despite clinical similarities and common TDP-43 
proteinopathy, the two cases present different neuropathological features. Noteworthy is the 
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observation of abundant TDP-43 oligodendroglial pathology in the lowest cortical layers and 
subcortical white matter of subject 1, with some of the inclusions being reminiscent of τ-ir 
GGI of WMT-GGI and aPSP-CSD. This may represent a newly identified TDP-43 variant 
of the spectrum of clinicopathological syndromes associated with GGI white matter 
pathology, which includes the tauopathies WMT-GGI, aPSP-CSD and sporadic MSTD, as 
well as the α-synucleinopathy MSA.569 Patient 2’s clinicopathological presentation 
resembles that of a 66-year-old man with rapidly progressive MND and PSP-like features, 
recently described by McCluskey et al.10 Beyond the more overt bulbar and limb weakness 
of that case, which fulfilled the diagnosis of ALS, the development of hypokinesia, rigidity 
and early postural instability were highly suggestive of PSP. In summary, our observations 
further support considering FTLD-MND with TDP-43 pathology in patients with a rapidly 
progressive PSP-like disorder, especially when accompanied by aphasia, dysarthria, and 
early-onset MND. The neuropathological substrate of this phenotype is heterogeneous and 
may include a newly identified variant of oligodendrogliopathy characterised by globular 
TDP-43-ir cytoplasmic inclusions.
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Magnetic MRI and post-mortem findings of patient 1. Axial sequences at the midbrain (A) 
and thalamic (B) levels showing mild temporal- and frontal-predominant cortical atrophy; 
mid-sagittal T1 weighted MRI (C) demonstrates mild thinning of the body and genu of the 
corpus callosum with relative preservation of the splenium, suggesting a reduction of 
interhemispheric frontotemporal fibres; midbrain appears of normal size. TAR DNA-
binding protein 43 (TDP-43) immunohistochemistry shows granular cytoplasmic deposits in 
the primary motor cortex (D). Neuronal cytoplasmic inclusions are abundant in the granule 
cell layer of the hippocampus (E). The subcortical white matter showed abundant pTDP-43 
oligodendroglial inclusions (F). Some oligodendroglial inclusions had typical appearance of 
globular inclusions (GGI, inset). Horizontal bar=10 μm.
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MRI and post-mortem findings of patient 2. Axial fluid-attenuated inversion recovery 
sequences at the lower (A) and higher thalamic (B) levels show mild insular enlargement 
with no overt frontal atrophy; mid-sagittal T1 weighted MRI (C) demonstrates mild thinning 
of the body of the corpus callosum with normal-appearing brainstem and cerebellar volume. 
TAR DNA-binding protein 43 immunohistochemistry shows neuronal cytoplasmic 
inclusions, some with ring-like perinuclear appearance, in the frontal cortical layer II (D) 
and dentate gyrus of the hippocampus (E). Granular and occasional skein-like inclusions are 
seen in a few residual upper motor neurons (F). Horizontal bar=10 μm.
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